• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

byNhat Hung (Benjamin) LamandKiera Liblik
June 29, 2022
in Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Registration for medical cannabis increased 4.5 times from 2016 to 2020 in the United States, with chronic pain and post-traumatic stress disorder (PTSD) being the most common conditions cited.

2. For states where recreational cannabis use was legalized, registration for medical use declined.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Access to cannabis has expanded across the United States, with 37 states legalizing medical cannabis use and 18 permitting recreational use in recent years. These state-specific policies conflict with federal law, deeming cannabis as a Schedule I drug. Such conflict has resulted in inconsistencies in cannabis access. For example, inappropriate indications for use, the absence of unified cannabis standards, and most recently, the crossover of recreational products into medical uses. This study examined state registry data for medical cannabis licensure between 2016 and 2020 to describe the trends of registration and patient-cited qualifying conditions. It was found that enrollment increased 4.5-fold during this period, a change that was consistent across all the reported states. Chronic pain and PTSD were noted as the most common reasons patients requested medical cannabis licenses. Conversely, enrollment declined in states where recreational use was legal. The study’s limitations included missing state data, lack of specific information about cannabis products, and lack of clarity on primary reasons for patients who reported “multiple conditions”. Overall, the study highlighted a rapid rise in the need for medical cannabis and the crossover of recreational products to medical use, emphasizing the need for renewed legislative discussion.

Click here to read the study in AIM

In-Depth [cross-sectional study]: The present study described medical cannabis licensure in the United States between 2016 and 2020. State registry data was examined to describe trends in medical cannabis enrollment, conditions reported by patients to qualify them for the license, and whether there was evidence of cannabis therapeutic value for such conditions. By 2020, 26 out of 37 states where medical cannabis was legalized reported the patient numbers, and 19 states reported patient-cited qualifying conditions. The total patient number was 2,974,433 in 2020, which was a 4.5-fold increase from 678,408 in 2016. The number of patients per 10,000 also showed a general upward trend, which was most dramatic in Oklahoma (78.1 per 10,000 in 2018 to 927.1 per 10,000 in 2020). By contrast, of the seven states with legalized recreational use, five saw a decrease in medical license registration. Among states where qualifying conditions were reported, chronic pain was the most common. It was cited by 484,386 patients in 2016, which rose to 1,119,668 in 2020 and accounted for 60.6% of all registered patients. PTSD was the second most common, increasing from 27,447 in 2016 to 195,984 in 2020 and accounting for 10.6% of all patients. The other conditions having substantial evidence of efficacy were chemotherapy-induced nausea and vomiting and multiple sclerosis-related spasticity. Notably, the overall percentage of these conditions declined from 84.6% of patients in 2016 to 68.2% in 2020. In summary, this study depicted a rapidly changing landscape of cannabis use and needs, both medical and recreational, and emphasized the need for coherent policies and continued research in this space.

Image: PD

RELATED REPORTS

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: cannabischronic diseasechronic painepidemiologymedical cannabismultiple sclerosispost-traumatic stress disorder (PTSD)public health
Previous Post

#VisualAbstract: Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

Next Post

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

RelatedReports

Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
Next Post
#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

Novel combination therapy may be effective for noncirrhotic HCV infection [UNITY-1 trial]

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options